We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ChromaDex Corp (CDXC) Common Stock USD0.001

Sell:$3.24 Buy:$3.44 Change: $0.18 (5.17%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $0.18 (5.17%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $0.18 (5.17%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Contact details

10900 Wilshire Blvd, Suite 600
United States
+1 (310) 3886706

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$274.21 million
Shares in issue:
75.54 million
Life Sciences Tools & Services
United States
US dollar

Key personnel

  • Robert Fried
    Chief Executive Officer, Director
  • Brianna Gerber
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.